JP2011524375A - ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用 - Google Patents

ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用 Download PDF

Info

Publication number
JP2011524375A
JP2011524375A JP2011513760A JP2011513760A JP2011524375A JP 2011524375 A JP2011524375 A JP 2011524375A JP 2011513760 A JP2011513760 A JP 2011513760A JP 2011513760 A JP2011513760 A JP 2011513760A JP 2011524375 A JP2011524375 A JP 2011524375A
Authority
JP
Japan
Prior art keywords
cancer
globo
factor
fut2
ssea3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011513760A
Other languages
English (en)
Japanese (ja)
Inventor
ユ，アリス，エル．
ユ，ジョン
ウォン，チ−フェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of JP2011524375A publication Critical patent/JP2011524375A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001173—Globo-H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011513760A 2008-06-16 2009-06-16 ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用 Pending JP2011524375A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6196808P 2008-06-16 2008-06-16
US61/061,968 2008-06-16
PCT/US2009/047537 WO2010005735A2 (en) 2008-06-16 2009-06-16 Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment

Publications (1)

Publication Number Publication Date
JP2011524375A true JP2011524375A (ja) 2011-09-01

Family

ID=41431519

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011513760A Pending JP2011524375A (ja) 2008-06-16 2009-06-16 ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
JP2011514633A Active JP5628158B2 (ja) 2008-06-16 2009-08-06 ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン
JP2014035431A Active JP5795655B2 (ja) 2008-06-16 2014-02-26 ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン
JP2015159196A Active JP6151319B2 (ja) 2008-06-16 2015-08-11 ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011514633A Active JP5628158B2 (ja) 2008-06-16 2009-08-06 ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン
JP2014035431A Active JP5795655B2 (ja) 2008-06-16 2014-02-26 ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン
JP2015159196A Active JP6151319B2 (ja) 2008-06-16 2015-08-11 ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン

Country Status (11)

Country Link
US (4) US20090317411A1 (enExample)
EP (2) EP2303286A4 (enExample)
JP (4) JP2011524375A (enExample)
KR (1) KR20110031949A (enExample)
CN (1) CN102065868A (enExample)
AU (2) AU2009268937A1 (enExample)
CA (2) CA2728344A1 (enExample)
ES (1) ES2570630T3 (enExample)
MX (2) MX350230B (enExample)
NZ (1) NZ590140A (enExample)
WO (2) WO2010005735A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017149723A (ja) * 2010-08-05 2017-08-31 シアトル ジェネティクス，インコーポレーテッド フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
JP2017532310A (ja) * 2014-09-15 2017-11-02 オービーアイ ファーマ，インコーポレイテッド 免疫原性／治療用糖コンジュゲート組成物およびその使用
JP2018510844A (ja) * 2015-01-24 2018-04-19 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんマーカーおよびその使用方法
JP2019515916A (ja) * 2016-04-22 2019-06-13 オービーアイ ファーマ，インコーポレイテッド グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
JP2019527690A (ja) * 2016-07-27 2019-10-03 オービーアイ ファーマ，インコーポレイテッド 免疫原性／治療用グリカン組成物およびその使用
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
US11833223B2 (en) 2016-03-29 2023-12-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US12053514B2 (en) 2013-09-17 2024-08-06 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
US12090212B2 (en) 2016-11-21 2024-09-17 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
CA2728574C (en) 2008-06-16 2020-10-20 Academia Sinica Cancer diagnosis based on levels of antibodies against globo h and its fragments
CN102065868A (zh) * 2008-06-16 2011-05-18 中央研究院 诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
CN107261129A (zh) 2010-05-03 2017-10-20 财团法人生物技术开发中心 用作疫苗的多糖与去毒大肠杆菌(e. coli)不耐热肠毒素(lt)的偶联
NZ604089A (en) * 2010-06-11 2015-03-27 Sloan Kettering Inst Cancer Multivalent glycopeptide constructs and uses thereof
GB201013767D0 (en) * 2010-08-17 2010-09-29 Isis Innovation Identification of ligands and their use
US20120288525A1 (en) 2011-05-11 2012-11-15 Chakravarty Sumana Pharmaceutical compositions comprising attenuated plasmodium sporozoites and glycolipid adjuvants
WO2013133220A1 (ja) * 2012-03-08 2013-09-12 学校法人産業医科大学 がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CA2883168A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
ES2843509T3 (es) * 2013-01-04 2021-07-19 Obi Pharma Inc Vacunas con mayor densidad de antígeno carbohidratado y nuevo adyuvante de saponina
JP6143240B2 (ja) 2013-05-02 2017-06-07 国立研究開発法人産業技術総合研究所 糖鎖抗原の免疫誘導剤
WO2014210397A1 (en) * 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) * 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
GB201313352D0 (en) 2013-07-26 2013-09-11 Isis Innovation Identification of peptide ligands
KR102298172B1 (ko) 2013-09-06 2021-09-06 아카데미아 시니카 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화
WO2016114819A1 (en) * 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937123A1 (en) * 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
MX2016012124A (es) 2014-03-19 2017-04-06 Mackay Medical Found The Presbyterian Church In Taiwan Mackay Memorial Hospital Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
JP2017512759A (ja) 2014-04-10 2017-05-25 オービーアイ ファーマ インコーポレイテッド 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途
US20150344585A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
AU2015267045B2 (en) * 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
FI3149045T3 (fi) * 2014-05-27 2023-03-20 Academia Sinica Koostumuksia ja menetelmiä, jotka liittyvät yleisglykoformeihin vasta-aineiden parannettua tehokkuutta varten
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
NZ729243A (en) 2014-08-22 2018-08-31 Academia Sinica Novel glycan conjugates and use thereof
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
WO2016044164A1 (en) * 2014-09-15 2016-03-24 Wayne State University Novel synthetic anticancer, antifungal, and antibacterial vaccines
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
AU2015378564A1 (en) * 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
KR102620346B1 (ko) 2015-01-30 2024-01-02 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
CN105067813A (zh) * 2015-07-23 2015-11-18 丁晓昆 一种快速检测t-合酶活性的方法
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
US11041017B2 (en) 2016-03-29 2021-06-22 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
TWI764917B (zh) 2016-08-22 2022-05-21 醣基生醫股份有限公司 抗體、結合片段及使用方法
TW201825522A (zh) * 2016-09-23 2018-07-16 張志隆 抗-globo h 抗體
TWI842710B (zh) * 2018-05-11 2024-05-21 台灣浩鼎生技股份有限公司 預測人體免疫反應的方法
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
US11958863B2 (en) 2018-11-02 2024-04-16 Siemens Healthcare Diagnostics Inc. Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544952B1 (en) * 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
CA2286798C (en) * 1997-04-16 2014-01-07 Sloan-Kettering Institute For Cancer Research Alpha-o-linked glycoconjugates with clustered(2,6)-st epitopes, methods of preparation and uses thereof
AU2001241783A1 (en) * 2000-02-29 2001-09-12 Sloan-Kettering Institute For Cancer Research Affinity matrix bearing tumor-associated antigens
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
AU2002354804A1 (en) 2001-07-06 2003-01-21 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
EP1434859A2 (en) * 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US7132101B2 (en) * 2002-02-27 2006-11-07 Duquesne University Of The Holy Ghost Compositions and methods for eliciting an immune response to gram-negative bacterial infections
AU2003277021A1 (en) * 2002-09-27 2004-04-19 Biomira, Inc. Glycosylceramide analogues
US20060035267A1 (en) * 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
WO2006068758A2 (en) * 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
US7534434B2 (en) 2004-12-28 2009-05-19 The Rockefeller University Glycolipids and analogues thereof as antigens for NK T cells
KR100764678B1 (ko) * 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
WO2008005824A1 (en) * 2006-06-30 2008-01-10 The Scripps Research Institute Adjuvants and methods of use
CN101225383B (zh) * 2007-01-15 2011-10-12 燕秋 用于抑制LeY糖抗原合成的岩藻糖基转移酶Ⅰ和Ⅳ的RNA干涉序列及重组干涉质粒
GB0703369D0 (en) * 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
CA2678618C (en) * 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cd1d molecules
WO2008128207A1 (en) * 2007-04-13 2008-10-23 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
AU2008259423A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
CN102065868A (zh) * 2008-06-16 2011-05-18 中央研究院 诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途
US8383767B2 (en) * 2008-06-27 2013-02-26 Academia Sinica Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain
US7928077B2 (en) * 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017149723A (ja) * 2010-08-05 2017-08-31 シアトル ジェネティクス，インコーポレーテッド フコースアナログを用いるイン・ビボでのタンパク質フコシル化の阻害方法
US12053514B2 (en) 2013-09-17 2024-08-06 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
JP2017532310A (ja) * 2014-09-15 2017-11-02 オービーアイ ファーマ，インコーポレイテッド 免疫原性／治療用糖コンジュゲート組成物およびその使用
JP7329006B2 (ja) 2015-01-24 2023-08-17 アカデミア シニカ 乳がん幹細胞の腫瘍原性を予測する方法
JP2018510844A (ja) * 2015-01-24 2018-04-19 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんマーカーおよびその使用方法
JP2021104998A (ja) * 2015-01-24 2021-07-26 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんマーカーおよびその使用方法
US11833223B2 (en) 2016-03-29 2023-12-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
JP2019515916A (ja) * 2016-04-22 2019-06-13 オービーアイ ファーマ，インコーポレイテッド グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
JP7544465B2 (ja) 2016-04-22 2024-09-03 オービーアイ ファーマ，インコーポレイテッド グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
US11583577B2 (en) 2016-04-22 2023-02-21 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
JP2022153505A (ja) * 2016-07-27 2022-10-12 オービーアイ ファーマ，インコーポレイテッド 免疫原性／治療用グリカン組成物およびその使用
US11642400B2 (en) 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
JP2019527690A (ja) * 2016-07-27 2019-10-03 オービーアイ ファーマ，インコーポレイテッド 免疫原性／治療用グリカン組成物およびその使用
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
US12090212B2 (en) 2016-11-21 2024-09-17 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods

Also Published As

Publication number Publication date
US9603913B2 (en) 2017-03-28
CA2728344A1 (en) 2010-01-14
US20150273034A1 (en) 2015-10-01
NZ590140A (en) 2012-07-27
JP2011524417A (ja) 2011-09-01
US20100136042A1 (en) 2010-06-03
KR20110031949A (ko) 2011-03-29
EP2303286A4 (en) 2011-12-28
EP2310047A1 (en) 2011-04-20
EP2310047B1 (en) 2016-03-30
JP5795655B2 (ja) 2015-10-14
EP2303286A2 (en) 2011-04-06
MX2010013932A (es) 2013-03-01
CN102065868A (zh) 2011-05-18
WO2010005598A1 (en) 2010-01-14
AU2009269127B2 (en) 2013-12-05
US9028836B2 (en) 2015-05-12
WO2010005735A3 (en) 2010-03-18
JP2014144958A (ja) 2014-08-14
JP6151319B2 (ja) 2017-06-21
JP5628158B2 (ja) 2014-11-19
JP2016020363A (ja) 2016-02-04
WO2010005735A2 (en) 2010-01-14
AU2009268937A1 (en) 2010-01-14
CA2728341A1 (en) 2010-01-14
CA2728341C (en) 2019-07-02
MX350230B (es) 2017-08-30
AU2009269127A1 (en) 2010-01-14
US8268969B2 (en) 2012-09-18
US20120328646A1 (en) 2012-12-27
US20090317411A1 (en) 2009-12-24
ES2570630T3 (es) 2016-05-19

Similar Documents

Publication Publication Date Title
JP2011524375A (ja) ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
RU2600798C2 (ru) Композиции вакцин и способы их применения
Xia et al. Low molecular weight heparin-coated and dendrimer-based core-shell nanoplatform with enhanced immune activation and multiple anti-metastatic effects for melanoma treatment
Boado RNA interference and nonviral targeted gene therapy of experimental brain cancer
US20190255090A1 (en) Egfr gene expression-suppressing sirna, precursor of same, and applications thereof
Shen et al. ICAM3 mediates tumor metastasis via a LFA-1-ICAM3-ERM dependent manner
CN106794194A (zh) 用于癌症治疗的介白素‑17受体b（il‑17rb）及其配体il‑17b之拮抗剂
US9284557B2 (en) Double-stranded nucleic acid molecule, cancer cell proliferation inhibitor and pharmaceutical agent suitable for prevention or treatment of cancer
CN120437284A (zh) 靶向FomA的mRNA疫苗及其在食管鳞癌免疫治疗中的应用
WO2025061011A1 (zh) 调节体内腺苷含量的方法和抗肿瘤的试剂
CN102051362B (zh) 靶向hpip基因的干扰性rna、含有该干扰性rna的药物组合物及其应用
AU2014201215B2 (en) Globo h and related anti-cancer vaccines with novel glycolipid adjuvants
TW201124159A (en) Small interference RNA molecule and applications thereof
US20230398144A1 (en) Exosomes containing mirnas targeting her2 synthesis and pharmaceutical compositions
CN121041241A (zh) 一种双基因沉默、cRGD修饰的靶向LNP及其结直肠癌抗血管生成应用
Akkaya et al. Immunization with a T cell-dependent protein antigen adjuvanted with DOTAP-CpG-B but not DOTAP-CpG-A induces robust germinal center responses and high affinity antibodies
JP5976922B2 (ja) 二本鎖核酸分子、ｄｎａ、ベクター、癌細胞増殖抑制剤、及び医薬
Finlay Nanoparticle Delivery of siRNA for the Silencing of TWIST1 in Metastatic Cancer
HK1153645B (en) Globo h and related anti-cancer vaccines with novel glycolipid adjuvants
CN101168065A (zh) 重组古菌组蛋白HPhA作为基因药物载体及在制备抗癌药物方面的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110405